Pfizer Q1 FY26 reported EPS drops 10% to $0.47; revenue rises 5% to $14.5 billion
Pfizer posted first-quarter 2026 revenue of USD 14.5 billion, up 5% year over year, while reported diluted EPS fell 10% to USD 0.47.Reported net income attributable to common shareholders slipped 9% to USD 2.69 billion, while adjusted diluted EPS dropped 18% to USD 0.75.First-quarter revenue rose 2% on an operational basis, driven by gains in Padcev, Eliquis, oncology biosimilars, and Nurtec, partly offset by declines in Comirnaty and Paxlovid.Full-year 2026 guidance was reaffirmed, with revenue seen at USD 59.5 billion to USD 62.5 billion and adjusted diluted EPS at USD 2.80 to USD 3.00.CEO Albert Bourla flagged positive Phase 3 readouts and momentum in oncology and obesity, while CFO David Denton highlighted 22% operational revenue growth from launched and acquired products.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information